Related Experiment Video
Updated: Feb 24, 2026
The Chick Chorioallantoic Membrane In Vivo Model to Assess Perineural Invasion in Head and Neck Cancer
Published on: June 21, 2019
Establishment and genomic characterization of the new chordoma cell line Chor-IN-1
Roberta Bosotti1, Paola Magnaghi2, Sebastiano Di Bella2
1Oncology, Nerviano Medical Sciences, Nerviano, (MI), Italy. roberta.bosotti@nervianoms.com.
Abstract:
Chordomas are rare, slowly growing tumors with high medical need, arising in the axial skeleton from notochord remnants. The transcription factor "brachyury" represents a distinctive molecular marker and a key oncogenic driver of chordomas. Tyrosine kinase receptors are also expressed, but so far kinase inhibitors have not shown clear clinical efficacy in chordoma patients. The need for effective therapies is extremely high, but the paucity of established chordoma cell lines has limited preclinical research. Here we describe the isolation of the new Chor-IN-1 cell line from a recurrent sacral chordoma and its characterization as compared to other chordoma cell lines. Chor-IN-1 displays genomic identity to the tumor of origin and has morphological features, growth characteristics and chromosomal abnormalities typical of chordoma, with expression of brachyury and other relevant biomarkers. Chor-IN-1 gene variants, copy number alterations and kinome gene expression were analyzed in comparison to other four chordoma cell lines, generating large scale DNA and mRNA genomic data that can be exploited for the identification of novel pharmacological targets and candidate predictive biomarkers of drug sensitivity in chordoma. The establishment of this new, well characterized chordoma cell line provides a useful tool for the identification of drugs active in chordoma.
Insights
A new chordoma cell line, Chor-IN-1, was developed from patient tumor samples. This cell line aids in identifying new drug targets and biomarkers for treating rare axial skeleton chordomas.
Area of Science:
- Oncology
- Genetics
- Molecular Biology
Background:
- Chordomas are rare axial skeleton tumors originating from notochord remnants.
- Brachyury is a key oncogenic driver in chordomas, while kinase inhibitors have shown limited efficacy.
- Limited availability of chordoma cell lines hinders preclinical research and drug development.
Purpose of the Study:
- To establish and characterize a new chordoma cell line, Chor-IN-1, for preclinical research.
- To compare Chor-IN-1 with existing cell lines for genomic and biomarker expression.
- To generate genomic data for identifying novel therapeutic targets and predictive biomarkers in chordoma.
Main Methods:
- Isolation and characterization of the Chor-IN-1 cell line from a recurrent sacral chordoma.
- Genomic analysis including gene variants, copy number alterations, and kinome gene expression.
- Comparative analysis of Chor-IN-1 against four other established chordoma cell lines.
Main Results:
- Chor-IN-1 exhibits genomic identity to the primary tumor and typical chordoma characteristics.
- The cell line expresses key biomarkers, including brachyury.
- Comprehensive genomic data (DNA and mRNA) were generated for comparative analysis.
Conclusions:
- The newly established Chor-IN-1 cell line is a valuable tool for chordoma research.
- This cell line facilitates the identification of potential pharmacological targets.
- Chor-IN-1 can aid in discovering predictive biomarkers for drug sensitivity in chordoma patients.
More Related Videos
08:09Isolation of Chondrocytes and Chondroprogenitors Using Fibronectin Adhesion and Migratory Assay
Published on: October 4, 2024
06:40Visualization of Chondrocyte Intercalation and Directional Proliferation via Zebrabow Clonal Cell Analysis in the Embryonic Meckel’s Cartilage
Published on: October 21, 2015